CLOs on the Move

Celmatix

www.celmatix.com

 
Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.celmatix.com
  • 14 Wall Street Suite 16D
    New York, NY USA 10005
  • Phone: 646.389.0245

Executives

Name Title Contact Details

Similar Companies

Cell Signaling Technology

Cell Signaling Technology, Inc. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

AiLife Diagnostics

AiLife Diagnostics is a CAP/CLIA laboratory that provides end-to-end genomic testing, interpretation services, and NGS analysis tool.

Freenome

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.

Hawaii Chitopure

Hawaii Chitopure is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Avectas

Avectas is a cell engineering technology business developing a unique delivery platform to enable the ex vivo manufacture of gene-modified cell therapy products, which will retain high in vivo functionality. Our vision is to position the non-viral SOLUPORE® cell engineering technology to be integrated into manufacturing processes for multiple autologous and allogeneic therapies and commercialised through development and license agreements.